A New Milestone in Colon Cancer Treatment Genentech has announced a significant development in oncology with the FDA approval of Tecentriq (atezolizumab) in combination with fluoropyrimidine- and oxaliplatin-based chemotherapy. This treatment is now indicated as an adjuvant therapy for patients with stage IIB or IIC colon cancer that has been completely resected. Understanding the Indication…